These Nasdaq stocks have led the bounce since 'liberation day' back to all-time highs

The S&P 500's recent all-time high and the Nasdaq Composite's over 15% surge since early April are largely attributed to a concentrated rebound in select growth stocks. CNBC Pro highlighted specific Nasdaq members with market caps over $5 billion that have led this recovery, possessing strong analyst conviction and significant implied upside. Examples include BridgeBio Pharma, up over 30% since April following an FDA orphan drug designation, and AppLovin, which rallied over 19% due to better-than-expected earnings, both demonstrating high analyst buy ratings and price targets suggesting over 34% further gains.

Analysis

The current market rally, which has seen the S&P 500 reach a new all-time high and the Nasdaq Composite surge over 15% since April 2nd, is being driven by a concentrated group of high-performing stocks rather than a broad-based recovery. A quantitative screen of Nasdaq-listed companies with market capitalizations over $5 billion reveals that leaders share common traits: strong analyst conviction (at least 65% buy ratings) and significant remaining upside (average price targets of 15% or more). BridgeBio Pharma (BBIO) exemplifies this trend, having surged over 30% since April, driven by the FDA granting orphan drug status for its infigratinib treatment; analysts project further upside of over 34%. Similarly, AppLovin (APP) rallied over 19% in the same period following a better-than-expected earnings report, with Wall Street's average price target implying a potential 41% increase. This data indicates that the market is rewarding companies with specific, positive fundamental catalysts, and that despite recent strong performance, analyst consensus suggests these select names have further room to appreciate.

Key Decisions for Investors

• Consider focusing on companies with clear, near-term fundamental catalysts, such as regulatory approvals or earnings beats, as these factors are key drivers of outperformance in the current market.
• For momentum-driven names like BBIO and APP that have already seen significant gains, use analyst consensus and price target upside as a validation tool before initiating or adding to a position.
• Given the recovery is led by a select group of stocks, investors should be mindful of portfolio concentration and monitor whether market leadership begins to broaden or if these specific names continue to carry the indices.